VPTDF - Ventripoint Issues Option Grants and Exercises
(TheNewswire)
Toronto, Ontario - TheNewswire - January 27, 2021 - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the“ Corporation ”, ( TSXV:VPT ) ( OTC:VPTDF) announces that on January 19, 2021 the Board of Directorsapproved the granting of 825,000 options to consultants at exerciseprices from $0.135 to $0.20 for a term of 1 year, with vesting over 4 months. TheCorporation is also announcing that 900,000 options with an exerciseprice of $0.10 have been exercised in the January 2021. TheCorporation now has 1,567,435 options available for future grantsunder the Stock Option Plan as approved by shareholders at the lastSpecial and Annual General Meeting on December 14, 2020.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in theapplication of AI (Artificial Intelligence) to echocardiography.Ventripoint's VMS products are powered by its proprietary KBRtechnology, which is the result of a decade of development andprovides accurate volumetric cardiac measurements equivalent to MRI.This affordable, gold-standard alternative allows cardiologistsgreater confidence in the management of their patients. Providingbetter care to patients serves as a springboard and basic standard forall of Ventripoint's products that guide our future developments. Inaddition, VMS+ is versatile and can be used with all ultrasoundsystems from any vendor supported by regulatory market approvals inthe U.S., Europe and Canada.
For further information, pleasecontact:
Mr . Peter Weichler,Director
Email : peter@weichler.ca
Or
Mr. Clay Chase
Email: cc@sdthc.com
Phone: 858-456-7300
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Copyright (c) 2021 TheNewswire - All rights reserved.